Clinical Trial Update: Iberdomide and Daratumumab As Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating Iberdomide in combination with Daratumumab as maintenance therapy after autologous stem cell transplant for multiple myeloma, and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Daratumumab (daratumumab)
• iberdomide (iberdomide)

Snippet

Sponsor: Barbara Ann Karmanos Cancer Institute | Conditions: Multiple Myeloma | Phase 2 | Status: RECRUITING